Androgen insensitivity syndrome medical therapy: Difference between revisions
No edit summary |
|||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Androgen insensitivity syndrome}} | {{Androgen insensitivity syndrome}} | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} {{ARK}} | ||
==Overview== | ==Overview== | ||
Revision as of 00:10, 7 July 2017
|
Androgen insensitivity syndrome Microchapters |
|
Differentiating Androgen insensitivity syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Androgen insensitivity syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Androgen insensitivity syndrome medical therapy |
|
Directions to Hospitals Treating Androgen insensitivity syndrome |
|
Risk calculators and risk factors for Androgen insensitivity syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aravind Reddy Kothagadi M.B.B.S[2]
Overview
Androgen insensitivity syndrome (AIS) results from androgen receptor dysfunction and is a common cause of disorder of sex development. The AIS phenotype largely depends on the degree of residual androgen receptor (AR) activity. [1]
Medical Therapy
- A multidisciplinary approach is recommended for clinical management from infancy through to adulthood.[1]
- Hormone replacement therapy is needed following gonadectomy.
- Patients who choose to retain the gonads are at risk of developing germ cell tumors for which sensitive circulating tumor markers may soon become available.
References
- ↑ 1.0 1.1 Mongan NP, Tadokoro-Cuccaro R, Bunch T, Hughes IA (2015). "Androgen insensitivity syndrome". Best Pract Res Clin Endocrinol Metab. 29 (4): 569–80. doi:10.1016/j.beem.2015.04.005. PMID 26303084.